Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 1 DiabetesIssue 527

Potential for Diabetes Patients to Create Their Own Insulin

Researchers have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of Type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.... 

Advertisement

The findings are important because, until now, it has been generally believed that, in humans, beta cells divide only very infrequently after the first year or so of life and that they do not readily proliferate once Type 1 diabetes is diagnosed. By studying the same unique collection of pancreas specimens that last year led the research team to conclude that some cases of Type 1 diabetes may have a viral cause, this current study presents evidence that there is a 10-fold increase in islet cell replication in patients recently diagnosed with Type 1 diabetes. A similar response had been seen previously in an animal model of Type 1 diabetes by a member of the team, Professor Adrian Bone (University of Brighton) but it was not known if accelerated β-cell replication also occurs in human patients.

The factors that trigger the replication process in patients with Type 1 diabetes are still unclear, although the study shows a correlation with the infiltration of immune cells (which suggests that an immune mediator is likely to be involved).

The results of the research offer the hope that, in future, it might be possible to encourage a newly diagnosed Type 1 diabetes patient's own beta cells to reproduce as a means of replacing those being destroyed by the disease. The development of such a therapy could mean that some patients with Type 1 diabetes would be able to produce their own insulin for a longer period, thereby reducing the need for pharmaceutical interventions.

Professor Noel Morgan, Director of the Institute of Biomedical and Clinical Sciences at the Peninsula Medical School, commented: "Our findings are significant because they challenge current thinking and offer the hope that, at some point in the future, a therapy could be developed that would allow individuals who are developing Type 1 diabetes to retain their own insulin. We are a long way from this point, but the first steps have been taken with this research."

He added: "We could not have come to our current conclusions without access to the unique collection of pancreas specimens from patients who died soon after being diagnosed with Type 1 diabetes, which was collected by our colleague Dr. Alan Foulis from the Department of Pathology at Glasgow Royal Infirmary. The specimens are allowing us to investigate the cellular processes that occur in the beta cells of people with Type 1 diabetes in a way that has not been possible before."

Published on-line at Diabetologia June 2010

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 25 June, 2010 and appeared in  MedicationType 1 DiabetesIssue 527

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Category: Nutrition
CE Credits: .5